

World Journal of *Gastroenterology*

World J Gastroenterol 2023 September 21; 29(35): 5094-5179



REVIEW

- 5094 Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancer
Zhou B, Zhang SR, Chen G, Chen P

ORIGINAL ARTICLE**Basic Study**

- 5104 Regenerating gene 4 promotes chemoresistance of colorectal cancer by affecting lipid droplet synthesis and assembly
Zhang CY, Zhang R, Zhang L, Wang ZM, Sun HZ, Cui ZG, Zheng HC

Retrospective Cohort Study

- 5125 Clinical characteristics and outcome of autoimmune pancreatitis based on serum immunoglobulin G4 level: A single-center, retrospective cohort study
Zhou GZ, Zeng JQ, Wang L, Liu M, Meng K, Wang ZK, Zhang XL, Peng LH, Yan B, Pan F

Retrospective Study

- 5138 Machine learning-based decision tool for selecting patients with idiopathic acute pancreatitis for endosonography to exclude a biliary aetiology
Sirtl S, Żorniak M, Hohmann E, Beyer G, Dibos M, Wandel A, Phillip V, Ammer-Herrmenau C, Neesse A, Schulz C, Schirra J, Mayerle J, Mahajan UM

Clinical Trials Study

- 5154 Heparanase inhibition leads to improvement in patients with acute gastrointestinal injuries induced by sepsis
Chen TT, Lv JJ, Chen L, Li M, Liu LP

Observational Study

- 5166 Lowering the threshold of alanine aminotransferase for enhanced identification of significant hepatic injury in chronic hepatitis B patients
Yu HS, Jiang H, Li MK, Yang BL, Smayi A, Chen JN, Wu B, Yang YD

CORRECTION

- 5178 Correction to "Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives"
Roy S, Dhaneshwar S

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Konstantinos Triantafyllou, MD, PhD, FEBGH, Full Professor, Hepatogastroenterology Unit, Second Department of Internal Medicine-Propaedeutic, Medical School, National and Kapodistrian University of Athens, "Attikon" University General Hospital, Athens 12462, Greece. ktriant@med.uoa.gr

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG*, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJG* as 4.3; Quartile category: Q2. The *WJG*'s CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Yi-Xuan Cai*, Production Department Director: *Xiang Li*, Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Hou-Bao Liu (Biliary Tract Disease), Naohisa Yoshida (Gastrointestinal Endoscopy), Jian-Gao Fan (Chronic Liver Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

September 21, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Pancreatic Cancer Institute, Fudan University

Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<WebSite><https://www.wjgnet.com/bpg/GerInfo/310></WebSite>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER'S OFFICIAL WEBSITE

<WebSite><https://www.shca.org.cn/></WebSite><NewLine/>

<WebSite><https://www.zs-hospital.sh.cn/></WebSite>



Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”

Supriya Roy, Suneela Dhaneshwar

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A, A

Grade B (Very good): 0

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Salvadori M, Italy; Zhu L, China

Received: August 16, 2023

Peer-review started: August 16, 2023

First decision: August 25, 2023

Revised: August 25, 2023

Accepted: September 1, 2023

Article in press: September 1, 2023

Published online: September 21, 2023



Supriya Roy, Department of Pharmacology, Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Noida 201303, Uttar Pradesh, India

Suneela Dhaneshwar, Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai 410206, Maharashtra, India

Corresponding author: Suneela Dhaneshwar, PhD, Academic Research, Director, Pharmacist, Professor, Department of Pharmaceutical Chemistry, Amity Institute of Pharmacy, Amity University Maharashtra, Mumbai-Pune Expressway, Bhatan, Post-Somathne, Panvel, Mumbai 410206, Maharashtra, India. suneeladhaneshwar@rediffmail.com

Abstract

Correction to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”. In this article, a correction note is to be added.

Key Words: Ulcerative colitis; Crohn's disease; Pouchitis; Dysbiosis; Microbiota; Inflammation

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This manuscript is to add a “correction note” to “Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]”.

Citation: Roy S, Dhaneshwar S. Correction to “Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives”. *World J Gastroenterol* 2023; 29(35): 5178-5179

URL: <https://www.wjgnet.com/1007-9327/full/v29/i35/5178.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v29.i35.5178>

TO THE EDITOR

Correction to: Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; 29(14): 2078-2100.

In this article, a correction note is to be added[1]. The corresponding author received a mail from Dr. Claudio De Simone sharing his concern about a probiotic formulation VSL#3 which is mentioned in this review article. Dr. Claudio wishes us to publish a corrigendum. It is an earnest request that please incorporate the following correction note and publish a corrigendum regarding the same.

Correction note: This review article includes references to several studies that investigated a probiotic formulation formerly marketed as VSL#3 which is currently, generically referred to as the “De Simone Formulation”. It is important to note that the current product marketed as VSL#3 differs from the De Simone Formulation as also stated by the federal court of Maryland in the Civil Action, No. TDC-15-1356. They are distinct probiotic formulations with different compositions and characteristics. Currently, the De Simone Formulation is accessible under Vivomixx (in Europe) and Visbiome (in the United States) brand names.

FOOTNOTES

Author contributions: Dhaneshwar S conceived the idea and designed the review article protocol, edited the final draft of the manuscript; Roy S collected the data and wrote the paper; and all authors reviewed and approved the manuscript.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: India

ORCID number: Supriya Roy 0000-0002-8676-5113; Suneela Dhaneshwar 0000-0001-7646-642X.

S-Editor: Fan JR

L-Editor: A

P-Editor: Fan JR

REFERENCES

- 1 Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives. *World J Gastroenterol* 2023; 29: 2078-2100 [PMID: 37122604 DOI: 10.3748/wjg.v29.i14.2078]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: bpgoffice@wjgnet.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

